Focused On-demand Library for Potassium voltage-gated channel subfamily H member 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9NS40

UPID:

KCNH7_HUMAN

Alternative names:

Ether-a-go-go-related gene potassium channel 3; Voltage-gated potassium channel subunit Kv11.3

Alternative UPACC:

Q9NS40; Q53QU4; Q53TB7; Q53TP9; Q8IV15

Background:

The Potassium voltage-gated channel subfamily H member 7, also known as Ether-a-go-go-related gene potassium channel 3 and Voltage-gated potassium channel subunit Kv11.3, plays a crucial role in cellular excitability. As the pore-forming alpha subunit of voltage-gated potassium channels, its activity is essential for the proper functioning of cardiac and nervous tissues. Channel properties can be influenced by cAMP levels and the assembly of different subunits, highlighting its complex regulatory mechanisms.

Therapeutic significance:

Understanding the role of Potassium voltage-gated channel subfamily H member 7 could open doors to potential therapeutic strategies. Its pivotal function in regulating heart rhythm and neuronal excitability positions it as a key target for drug discovery efforts aimed at treating arrhythmias and neurological disorders.